Hupamsi Tablets 250 mg (Famciclovir)

Adult dose

1. Treatment of herpes zoster Adults: Take 250 mg of famciclovir orally 3 times daily for 7 days. It is preferable to start treatment as soon as symptoms appear after infection. 2. Treatment of an initial episode of genital herpes Adults: Take 250 mg of this medicine orally 3 times daily for 5 days. It is preferable to start treatment as soon as symptoms appear after infection. 3. Treatment of acute recurrent genital herpes Adults: Take 125 mg of this medicine orally 2 times daily for 5 days. It is preferable to start treatment during the prodromal phase or as soon as symptoms appear after infection. 4. Suppression of recurrent genital herpes Adults: Take 250 mg of this medicine orally 2 times daily. Discontinue treatment periodically every 6～12 months to assess whether the natural course of the disease has changed. 5. Patients with renal impairment: Since the creatinine clearance of this medicine is reduced in patients with renal impairment, dosage adjustment should be made with caution. The dosage and administration for these patients are as follows. 1) Treatment of herpes zoster and an initial episode of genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59: 250 mg per dose, 2 times daily Creatinine clearance (mL/min/1.73㎡) 10～29: 250 mg per dose, 1 time daily 2) Treatment of acute recurrent genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59: 125 mg per dose, 2 times daily Creatinine clearance (mL/min/1.73㎡) 10～29: 125 mg per dose, 1 time daily 3) Suppression of recurrent genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59: 250 mg per dose, 2 times daily Creatinine clearance (mL/min/1.73㎡) 10～29: 125 mg per dose, 2 times daily 4) If only the serum creatinine level is known, creatinine clearance can be calculated using the following formula. Men: {body weight (kg) × (140-age)}/ {72 × serum creatinine (mg/dL)} Women: 0.85 × the value calculated for men 5) Patients with renal impairment undergoing hemodialysis For patients undergoing hemodialysis, it is preferable to administer the medicine every 48 hours, taking the interval between dialysis sessions into account. Since 4 hours of hemodialysis reduces the plasma concentration of this medicine by approximately 75%, administer it immediately after dialysis. The recommended dose is 250mg for patients with herpes zoster and 125mg for patients with genital herpes. 6. Patients with hepatic impairment: No dosage adjustment is required for patients with chronic compensated liver disease. There is insufficient treatment experience in patients with overt chronic decompensated liver disease, so a clear recommended dose has not been established.

This medication should not be used by certain patients. Those who have an allergic reaction to this medication or its components should not take it. In addition, since it contains lactose, patients with a genetic disorder that prevents them from digesting lactose should also avoid taking this medication. Care should be taken when using this medication in patients with impaired kidney function. When taking this medication, side effects such as headache or nausea may occur. Most are mild to moderate symptoms, and these symptoms can occur without taking the medication. Occasionally, there may be a decrease in platelet count or white blood cell count in the blood. Moreover, central nervous system symptoms such as dizziness, drowsiness, confusion, and hallucinations may occur rarely. Symptoms like rapid heartbeat or digestive issues such as nausea, vomiting, abdominal pain, and diarrhea can also occur frequently. Liver dysfunction or jaundice may occur, and skin rash, itching, hives, and swelling around the face or eyes may also appear. Patients with poor kidney function should be cautious as serious issues like acute renal failure may arise. This medication does not completely cure genital herpes, so it is advisable to avoid sexual contact if symptoms are present during treatment. Safe sexual practices are also recommended. There is no clear evidence that this medication affects driving or operating machinery, but precautions should be taken if dizziness or drowsiness occurs. Patients with slightly impaired liver function do not require special dose adjustments, but effectiveness may be reduced in patients with severe liver dysfunction. The potential for drug interactions with this medication is low; however, care should be taken as blood concentration may change when taken with certain medications. Women who are pregnant or breastfeeding should consult their physician before taking this medication, and women who may become pregnant should also take it with caution. Children under 18 years of age should not use it since its safety and efficacy have not been established. Generally, elderly patients do not require dose adjustments, but adjustments must be made if kidney function is reduced. In case of overdose, immediate treatment should be sought, and blood dialysis can reduce the drug concentration. Store below 30 degrees Celsius in a dry place and keep out of reach of children. Be careful as transferring to another container may diminish quality.

• headache
• nausea
• thrombocytopenia
• leukopenia
• neutropenia
• dizziness
• confusion
• drowsiness
• hallucinations
• palpitations

This medication should be stored in a sealed container to prevent moisture and should be kept in a dry place below 30 degrees Celsius. Storing it this way can maintain the effectiveness of the medication for a longer period.

Appearance

White round film-coated tablet

Package unit

21 tablets (7 tablets/PTP x 3)